Meeting
2011 ASCO Annual Meeting
A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727).
Authors
E. Jonasch
University of Texas M. D. Anderson Cancer Center, Houston, TX
E. Jonasch , P. Lara Jr., N. M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01239342
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS192)
Abstract #
TPS192
Poster Bd #
47F
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01.
First Author: Jeffrey J. Raizer
Poster
2021 Genitourinary Cancers Symposium
Biomarker-based phase II study of sapanisertib (TAK-228), an mTORC1/2 inhibitor in patients with refractory metastatic renal cell carcinoma (mRCC).
First Author: Bradley Alexander McGregor
Poster
2018 Genitourinary Cancers Symposium
Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF).
First Author: Yasser Ged
Poster
2016 ASCO Annual Meeting
SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).
First Author: Brigitte C. Widemann